Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Boric Acid SCHEMBL31176956 | 0.93 | PDGFRB (0.39) | LPLLIPGPDGFRBKDRFFAR1 | |
| SCHEMBL2872042 | 0.85 | PDGFRB (0.43) | LPLLIPGPDGFRBKDRFFAR1 | |
| SCHEMBL12537248 | 0.84 | PDGFRB (0.30) | PDGFRBKDR | |
| SCHEMBL15916971 | 0.82 | DGAT1 (0.53) | LPLLIPGPDGFRBKDRCA1 | |
| SCHEMBL1284338 | 0.81 | LPL (0.42) | LPLLIPGFFAR1CA1CA2 | |
| SCHEMBL28088657 | 0.81 | PDGFRB (0.30) | PDGFRBKDR | |
| SCHEMBL15936842 | 0.79 | FEN1 (0.48) | LPLLIPGPDGFRBKDRAAK1 | |
| SCHEMBL20315296 | 0.79 | FFAR1 (0.42) | LPLLIPGPDGFRBKDRFFAR1 | |
| SCHEMBL20137083 | 0.79 | LPL (0.48) | LPLLIPGFFAR1CA1CA2 | |
| SCHEMBL28990423 | 0.79 | LPL (0.41) | LPLLIPGFFAR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1085 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326276-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | Natco Pharma Ltd (IN) | 2024-02-28 | — | — | EP | claimed |
| WO-2022224267-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2022-10-27 | — | — | WO | claimed |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | GLOBAL CANCER TECHNOLOGY INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4713095-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| EP-4415816-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4647076-A2 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier (FR) | 2025-11-12 | — | — | EP | disclosed |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| EP-1202955-A4 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6518306-B1 | PDE4 inhibitors particularly in regards to treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-6410728-B1 | BACTERICIDES; PSORIASIS; ANTIARTHRITIC AGENTS; TREATING TOXICITY DUE TO CHEMOTHERAPY; OBESITY; ANTIBIOTIC-RESISTANT STAPHYLOCOCCUS, MORAXELLA, ENTEROCOCCUS AND STREPTOCOCCUS; GRAMPOSITIVE BACTERIA | ABBOTT LABORATORIES | 2002-06-25 | — | — | US | disclosed |
| EP-1202955-A2 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SmithKline Beecham Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| US-20020045625-A1 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | ABBOTT LABORATORIES | 2002-04-18 | — | — | US | disclosed |
| WO-2002018353-A2 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001010385-A2 | 1,4-SUBSTITUTED 4,4-DIARYL CYCLOHEXANES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | LPL 1991/4885LIPG 3450/4885PDGFRB 3811/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | LPL 3855/4885LIPG 2672/4885PDGFRB 389/4885 |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3C2B, PIK3C2A, PIK3CA | LPL 2951/4885LIPG 3375/4885PDGFRB 467/4885 |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | PIK3R4, PIK3R1, ATG7 | LPL 1524/4885LIPG 1661/4885PDGFRB 616/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | LPL 559/4885LIPG 215/4885PDGFRB 1157/4885 |
| US-20020045625-A1 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | OXA1L, TK1, PDCD1 | LPL 4527/4885LIPG 4683/4885PDGFRB 3623/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | LPL 3263/4885LIPG 1906/4885PDGFRB 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.